Grant S, Rauscher F, Jakubowski A, Cadman E
Cancer Res. 1981 Feb;41(2):410-8.
The effect of N-phosphonacetyl-L-aspartate (PALA) pretreatment on the metabolism and cytotoxicity of 5-azacytidine (5-aza-Cyd) was studied in two murine leukemic cell lines. Exposure of P388 and L1210 cells to 3 mM PALA for 3 hr before adding 5-aza-Cyd at 75 microM was accompanied by a two-fold increment in acid-soluble and 3-fold increment in acid-insoluble incorporation of 5-aza-Cyd in both cell lines. RNA incorporation of 5-aza-Cyd increased from 97.5 +/- 3.4 pmol 5-aza-Cyd per microgram D-ribose in control cells to 299.2 +/- 4.2 pmol 5-aza-Cyd per microgram D-ribose in PALA-treated cells; a smaller increment in DNA incorporation of 5-aza-Cyd was also noted. Sequential treatment of cells with PALA and 5-aza-Cyd was associated with a 40% reduction in protein synthesis compared to only a 2 and 8% reduction, respectively, produced by the drugs given alone. Sequential administration of PALA and 5-aza-Cyd resulted in greater than additive cytotoxicity as measured by both growth inhibition and in vitro soft-agar cloning assays. Exposure of both cell lines to 3 mM PALA for 3 hr produced 50 and 65% reductions in intracellular levels of cytidine triphosphate and uridine triphosphate; intracellular accumulation of 5-azacytidine triphosphate, the lethal metabolite of 5-aza-Cyd, increased from 43.4 +/- 2.1 pmol/10(6) cells to 92.4 +/- 3.3 pmol/10(6) cells in PALA-treated cells. PALA was able to augment the metabolism and cytotoxicity of 5-aza-Cyd in a uridine-cytidine kinase-mutant 5-aza-Cyd-resistant L5178Y subline. This sequential drug combination has a rational biochemical basis and may offer significant advantages over either drug when administered alone, especially in cells which are resistant to 5-aza-Cyd.
在两种小鼠白血病细胞系中研究了 N-膦酰乙酰-L-天冬氨酸(PALA)预处理对 5-氮杂胞苷(5-aza-Cyd)代谢及细胞毒性的影响。在添加 75μM 的 5-aza-Cyd 之前,将 P388 和 L1210 细胞暴露于 3mM 的 PALA 中 3 小时,结果两种细胞系中 5-aza-Cyd 的酸溶性掺入增加了两倍,酸不溶性掺入增加了三倍。5-aza-Cyd 的 RNA 掺入从对照细胞中每微克 D-核糖 97.5±3.4pmol 的 5-aza-Cyd 增加到 PALA 处理细胞中每微克 D-核糖 299.2±4.2pmol 的 5-aza-Cyd;5-aza-Cyd 的 DNA 掺入也有较小幅度的增加。与单独给药相比,PALA 和 5-aza-Cyd 的序贯处理使蛋白质合成减少了 40%,而单独使用这两种药物时蛋白质合成分别仅减少了 2%和 8%。通过生长抑制和体外软琼脂克隆试验测定,PALA 和 5-aza-Cyd 的序贯给药导致细胞毒性大于相加作用。将两种细胞系暴露于 3mM 的 PALA 中 3 小时,使细胞内三磷酸胞苷和三磷酸尿苷水平分别降低了 50%和 65%;5-aza-Cyd 的致死代谢产物 5-氮杂胞苷三磷酸在细胞内的积累从 43.4±2.1pmol/10⁶细胞增加到 PALA 处理细胞中的 92.4±3.3pmol/10⁶细胞。PALA 能够增强 5-aza-Cyd 在尿苷-胞苷激酶突变的 5-aza-Cyd 耐药 L5178Y 亚系中的代谢和细胞毒性。这种序贯药物组合具有合理的生化基础,与单独使用任何一种药物相比可能具有显著优势,尤其是在对 5-aza-Cyd 耐药的细胞中。